After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to ...

The venture firm Vensana Capital has raised its third medtech-focused fund in the past six years, with $425 million in new ...

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

After Vanda Pharmaceuticals’ phase 3 miss and FDA rejection for its stomach disorder candidate, CEO Mihael Polymeropoulos, ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

Velia Therapeutics has announced it is winding down its operations while staying loyal to the therapeutic potential of ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...